Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.50 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287788 | 0.69 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL287619 | 0.69 | TRPV1 (0.46) | TRPV1TRPC5GPR119SRC | |
| SCHEMBL287641 | 0.69 | TRPV1 (0.66) | TRPV1 | |
| SCHEMBL2162201 | 0.67 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL28110943 | 0.64 | TRPV1 (0.63) | TRPV1SRC | |
| SCHEMBL30931611 | 0.64 | SRC (0.47) | TRPV1TRPC5SRCSIGMAR1 | |
| SCHEMBL287794 | 0.64 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL7619740 | 0.63 | ALDH1A1 (0.48) | SIGMAR1 | |
| SCHEMBL28968744 | 0.63 | ENO1 (0.67) | SRC | |
| SCHEMBL287557 | 0.63 | TRPV1 (0.61) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427435-B1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2017-06-14 | — | — | EP | claimed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | claimed |
| US-8592471-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2013-11-26 | — | — | US | claimed |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-10-11 | — | — | US | claimed |
| CN-102428071-A | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | GRUENENTHAL GMBH | 2012-04-25 | — | — | CN | claimed |
| EP-2427435-A1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-03-14 | — | — | EP | claimed |
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2010-12-30 | — | — | US | claimed |
| WO-2010127856-A1 | SUBSTITUTED PHENYLLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | claimed |
| EP-2427435-B1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2017-06-14 | — | — | EP | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9120756-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-8946204-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20150011592-A9 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-8592471-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| CN-102428071-A | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | GRUENENTHAL GMBH | 2012-04-25 | — | — | CN | disclosed |
| EP-2427435-A1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| WO-2010127856-A1 | SUBSTITUTED PHENYLLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885TRPC5 92/4885P2RX7 25/4885 |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | TRPV1 1/4885TRPC5 114/4885P2RX7 25/4885 |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | TRPV1 1/4885TRPC5 114/4885P2RX7 25/4885 |
| US-20150011592-A9 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885TRPC5 92/4885P2RX7 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.